8-K filed Jun 25, 2026 at 16:26 ET
Taysha Gene Therapies priced a $200M underwritten public offering of 32,500,001 common shares at $6.00/share and 833,333 pre-funded warrants at $5.999/warrant, alongside a 30-day underwriter option for up to 5,000,000 additional shares. The offering, closed simultaneously with this 8-K, was executed at a 13.5% discount to the prior day's close of $6.94, raising ~$187.4M in net proceeds (or ~$215.6M if the greenshoe is fully exercised). The company states these funds extend its cash runway into H2 2028. The dilutive transaction offsets the capital-extending benefit, making the net effect neutral with a modest negative bias from the discount.